Skip to main content Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Follow Incyte Corp Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licensing Rights Business Follow March 24 (Reuters) - Karyopharm Therapeutics (KPTI.O), opens new tabsaid on Tuesday its oncology therapy showed a statistically significant improvement in spleen volume in a lat ...